Table 3 Cost-effectiveness analysis results (base case)
Screening strategy | 1st and 2nd trimester screening (current screening) | NIPT as contingent testing | NIPT as first-line testing |
|---|---|---|---|
Effectiveness | |||
No of women undergoing 1st and 2nd trimester screening tests | 66,799 | 66,799 | 1336 |
No of women undergoing NIPT | 0 | 3152 | 66,799 |
No of NIPT with a positive result | 0 | 251 | 280 |
No of ITa | 3275 | 579 | 700 |
No of procedure-related miscarriages | 23 | 4 | 5 |
No of T21 cases detected | 271 | 269 | 296 |
Costs | |||
1st and 2nd trimester screening tests | €5,292,716 | €5,292,716 | €101,536 |
NIPT | €0 | €1,802,350 | €40,114,800 |
IT | €3,093,565 | €546,923 | €661,220 |
Hospitalisation due to amniotic fluid leakage and pregnancy termination owing to T21 | €515,591 | €469,362 | €518,389 |
Total costs | €8,901,872 | €8,111,351 | €41,395,745 |
Economic analysis | NIPT as first-line testing vs 1st and 2nd trimester screening | NIPT as contingent testing vs 1st and 2nd trimester screening | NIPT as first-line testing vs NIPT as contingent testing |
|---|---|---|---|
Incremental cost | €32,494,073 | €− 790,521 | €33,284,594 |
Incremental effectiveness (T21 extra cases detected) | 25 | − 2 | 27 |
ICER (€/T21 extra case detected) | 1,299,763 | – | 1,232,763 |